In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
All content for Rx for Biotech is the property of Podcast Host Chris Leidli and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt
Rx for Biotech
38 minutes 18 seconds
6 months ago
Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt
Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.
Rx for Biotech
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
